On March 19, 2026, Shanghai Escugen Biotechnology Co., Ltd. successfully passed the National High-Tech Enterprise certification and officially obtained the "High-Tech Enterprise" certificate. This qualification is a high recognition of Escugen Bio's comprehensive strength in innovative drug pipeline layout, ADC technology R&D, independent intellectual property accumulation, and transformation of scientific and technological achievements. It also demonstrates the company's steadfast commitment to independent innovation in the innovative drug field over the years.
The National High-Tech Enterprise certification is strictly reviewed according to the "Administrative Measures for the Recognition of High-Tech Enterprises" (Guo Ke Fa Huo [2016] No. 32) and "Guidelines for the Administration of High-Tech Enterprise Recognition" (Guo Ke Fa Huo [2016] No. 195) jointly issued by the Ministry of Science and Technology, the Ministry of Finance, and the State Taxation Administration. It covers multiple mandatory indicators including core independent intellectual property rights, proportion of scientific and technical personnel, R&D investment, and proportion of high-tech product revenue. It is an important symbol for measuring an enterprise's innovation capability, technological strength, and core competitiveness.
Since its establishment, Escugen has always aimed to develop globally leading Best/First-in-Class innovative drugs, focusing on innovative drug development in the fields of oncology and autoimmune diseases. Obtaining the National High-Tech Enterprise certification is an important milestone in Escugen's innovative development journey and a new starting point for continuously climbing technological peaks. In the future, Escugen will seize this opportunity to continue adhering to its original innovation mission, increase R&D investment, deepen its presence in the oncology and autoimmune disease fields, accelerate the clinical progress of core pipelines, continuously enhance independent innovation capabilities and comprehensive technological strength, promote the commercialization of innovative drug achievements, fully leverage the exemplary and leading role of high-tech enterprises, and contribute to industry development.
About Escugen
Shanghai Escugen Biotechnology Co., Ltd. was established in 2017 in Zhangjiang High-Tech Park, Pudong New Area, Shanghai. The company focuses on innovative drug development in the fields of oncology and autoimmune diseases. The founding team has decades of R&D experience in both international and domestic biopharmaceutical companies. The R&D team is professionally comprehensive, covering antibody engineering, conjugation technology, CMC, and clinical development, with an average of over 10 years of industry experience.
Escugen has pioneered the EZWi-Fit® linker-payload technology platform with global intellectual property rights. The clinical safety and efficacy of ADCs based on this platform technology have been preliminarily validated through ongoing clinical trials. Recently, multiple domestic and international partners have also advanced innovative target ADCs based on this platform into clinical trial phases.
